HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brunmair, B. Articles by Fürnsinn, C. Search for Related Content PubMed PubMed Citation Articles by Brunmair, B. Articles by Fürnsinn, C. Social Bookmarking                What's this?

Direct Thiazolidinedione Action on Isolated Rat Skeletal Muscle Fuel Handling Is Independent of Peroxisome Proliferator–Activated Receptor--Mediated Changes in Gene Expression

Department of Medicine III, Division of Endocrinology & Metabolism, University of Vienna, Austria

Thiazolidinediones (TZDs) are believed to induce insulin sensitization by modulating gene expression via agonistic stimulation of the nuclear peroxisome proliferator–activated receptor- (PPAR-). We have shown earlier that the TZD troglitazone inhibits mitochondrial fuel oxidation in isolated rat skeletal muscle. In the present study, rat soleus muscle strips were exposed to TZDs to examine whether the inhibition of fuel oxidation is mediated by PPAR- activation. Our findings consistently indicated direct, acute, and PPAR--independent TZD action on skeletal muscle fuel metabolism. Rapid stimulation of lactate release by 20 µmol/l troglitazone within 30 min suggested that direct TZD action on skeletal muscle in vitro does not rely on changes in gene expression rates (12.6 ± 0.6 [control] vs. 16.0 ± 0.8 µmol · g^-1 · h^-1 [troglitazone]; P < 0.01). This conclusion was supported by the failure of actinomycin D and cycloheximide to block the effects of troglitazone. Mitochondrial fuel oxidation was consistently inhibited by six different TZDs (percent inhibition of CO₂ production from palmitate after 25 h: troglitazone, -61 ± 2%; pioglitazone, -43 ± 7% ; rosiglitazone, -22 ± 6%; BM13.1258, -47 ± 9%; BM15.2054, -51 ± 4%; and T-174, -59 ± 4% [P < 0.005 each]), but not by PPAR- agonistic compounds not belonging to the TZD class (JTT-501, -5 ± 7% [NS]; prostaglandin J₂, 17 ± 7% [P < 0.05]), which further argues against dependence on PPAR- activation. In summary, our findings provided good evidence that direct inhibition of mitochondrial fuel oxidation in isolated skeletal muscle is a group-specific effect of TZDs and is independent of PPAR--mediated gene expression.

CiteULike

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				D. G. Haider, F. Mittermayer, G. Schaller, M. Artwohl, S. M. Baumgartner-Parzer, G. Prager, M. Roden, and M. Wolzt Free fatty acids normalize a rosiglitazone-induced visfatin release Am J Physiol Endocrinol Metab, November 1, 2006; 291(5): E885 - E890. [Abstract] [Full Text] [PDF]

				D. Safiulina, N. Peet, E. Seppet, A. Zharkovsky, and A. Kaasik Dehydroepiandrosterone Inhibits Complex I of the Mitochondrial Respiratory Chain and is Neurotoxic In Vitro and In Vivo at High Concentrations Toxicol. Sci., October 1, 2006; 93(2): 348 - 356. [Abstract] [Full Text] [PDF]

				N. K. LeBrasseur, M. Kelly, T.-S. Tsao, S. R. Farmer, A. K. Saha, N. B. Ruderman, and E. Tomas Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues Am J Physiol Endocrinol Metab, July 1, 2006; 291(1): E175 - E181. [Abstract] [Full Text] [PDF]

				J. Lopez-Soriano, C. Chiellini, M. Maffei, P. A. Grimaldi, and J. M. Argiles Roles of Skeletal Muscle and Peroxisome Proliferator-Activated Receptors in the Development and Treatment of Obesity Endocr. Rev., May 1, 2006; 27(3): 318 - 329. [Abstract] [Full Text] [PDF]

				S. J. Lessard, Z.-P. Chen, M. J. Watt, M. Hashem, J. J. Reid, M. A. Febbraio, B. E. Kemp, and J. A. Hawley Chronic rosiglitazone treatment restores AMPK{alpha}2 activity in insulin-resistant rat skeletal muscle Am J Physiol Endocrinol Metab, February 1, 2006; 290(2): E251 - E257. [Abstract] [Full Text] [PDF]

				R. A. Velliquette, J. E. Friedman, J. Shao, B. B. Zhang, and P. Ernsberger Therapeutic Actions of an Insulin Receptor Activator and a Novel Peroxisome Proliferator-Activated Receptor {gamma} Agonist in the Spontaneously Hypertensive Obese Rat Model of Metabolic Syndrome X J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 422 - 430. [Abstract] [Full Text] [PDF]

				I. Bogacka, H. Xie, G. A. Bray, and S. R. Smith Pioglitazone Induces Mitochondrial Biogenesis in Human Subcutaneous Adipose Tissue In Vivo Diabetes, May 1, 2005; 54(5): 1392 - 1399. [Abstract] [Full Text] [PDF]

				G. Llaverias, M. Vazquez-Carrera, R. M. Sanchez, V. Noe, C. J. Ciudad, J. C. Laguna, and M. Alegret Rosiglitazone upregulates caveolin-1 expression in THP-1 cells through a PPAR-dependent mechanism J. Lipid Res., November 1, 2004; 45(11): 2015 - 2024. [Abstract] [Full Text] [PDF]

				B. Brunmair, A. Lest, K. Staniek, F. Gras, N. Scharf, M. Roden, H. Nohl, W. Waldhausl, and C. Furnsinn Fenofibrate Impairs Rat Mitochondrial Function by Inhibition of Respiratory Complex I J. Pharmacol. Exp. Ther., October 1, 2004; 311(1): 109 - 114. [Abstract] [Full Text] [PDF]

				K. Shimomura, H. Shimizu, M. Ikeda, S. Okada, M. Kakei, S. Matsumoto, and M. Mori Fenofibrate, Troglitazone, and 15-Deoxy-{Delta}12,14-prostaglandin J2 Close KATP Channels and Induce Insulin Secretion J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 1273 - 1280. [Abstract] [Full Text] [PDF]

				B. Brunmair, K. Staniek, F. Gras, N. Scharf, A. Althaym, R. Clara, M. Roden, E. Gnaiger, H. Nohl, W. Waldhausl, et al. Thiazolidinediones, Like Metformin, Inhibit Respiratory Complex I: A Common Mechanism Contributing to Their Antidiabetic Actions? Diabetes, April 1, 2004; 53(4): 1052 - 1059. [Abstract] [Full Text] [PDF]

				A. N. Carley, L. M. Semeniuk, Y. Shimoni, E. Aasum, T. S. Larsen, J. P. Berger, and D. L. Severson Treatment of type 2 diabetic db/db mice with a novel PPAR{gamma} agonist improves cardiac metabolism but not contractile function Am J Physiol Endocrinol Metab, March 1, 2004; 286(3): E449 - E455. [Abstract] [Full Text]

				J. R. Colca, W. G. McDonald, D. J. Waldon, J. W. Leone, J. M. Lull, C. A. Bannow, E. T. Lund, and W. R. Mathews Identification of a novel mitochondrial protein ("mitoNEET") cross-linked specifically by a thiazolidinedione photoprobe Am J Physiol Endocrinol Metab, February 1, 2004; 286(2): E252 - E260. [Abstract] [Full Text] [PDF]

				H. M. Wilmsen, T. P. Ciaraldi, L. Carter, N. Reehman, S. R. Mudaliar, and R. R. Henry Thiazolidinediones upregulate impaired fatty acid uptake in skeletal muscle of type 2 diabetic subjects Am J Physiol Endocrinol Metab, August 1, 2003; 285(2): E354 - E362. [Abstract] [Full Text] [PDF]

				J. K. Kim, J. J. Fillmore, O. Gavrilova, L. Chao, T. Higashimori, H. Choi, H.-J. Kim, C. Yu, Y. Chen, X. Qu, et al. Differential Effects of Rosiglitazone on Skeletal Muscle and Liver Insulin Resistance in A-ZIP/F-1 Fatless Mice Diabetes, June 1, 2003; 52(6): 1311 - 1318. [Abstract] [Full Text] [PDF]

				A. J. Gilde, K. A.J.M. van der Lee, P. H.M. Willemsen, G. Chinetti, F. R. van der Leij, G. J. van der Vusse, B. Staels, and M. van Bilsen Peroxisome Proliferator-Activated Receptor (PPAR) {alpha} and PPAR{beta}/{delta}, but not PPAR{gamma}, Modulate the Expression of Genes Involved in Cardiac Lipid Metabolism Circ. Res., March 21, 2003; 92(5): 518 - 524. [Abstract] [Full Text] [PDF]

				C. Dello Russo, V. Gavrilyuk, G. Weinberg, A. Almeida, J. P. Bolanos, J. Palmer, D. Pelligrino, E. Galea, and D. L. Feinstein Peroxisome Proliferator-activated Receptor gamma Thiazolidinedione Agonists Increase Glucose Metabolism in Astrocytes J. Biol. Chem., February 14, 2003; 278(8): 5828 - 5836. [Abstract] [Full Text] [PDF]

				K. Ikeda, N. Emoto, M. Matsuo, and M. Yokoyama Molecular Identification and Characterization of a Novel Nuclear Protein Whose Expression Is Up-regulated in Insulin-resistant Animals J. Biol. Chem., January 31, 2003; 278(6): 3514 - 3520. [Abstract] [Full Text] [PDF]

				J.-M. Ye, G. Frangioudakis, M. A. Iglesias, S. M. Furler, B. Ellis, N. Dzamko, G. J. Cooney, and E. W. Kraegen Prior Thiazolidinedione Treatment Preserves Insulin Sensitivity in Normal Rats during Acute Fatty Acid Elevation: Role of the Liver Endocrinology, December 1, 2002; 143(12): 4527 - 4535. [Abstract] [Full Text] [PDF]

				L. G. D. Fryer, A. Parbu-Patel, and D. Carling The Anti-diabetic Drugs Rosiglitazone and Metformin Stimulate AMP-activated Protein Kinase through Distinct Signaling Pathways J. Biol. Chem., July 5, 2002; 277(28): 25226 - 25232. [Abstract] [Full Text] [PDF]

				H. B. Hartman, X. Hu, K. X. Tyler, C. K. Dalal, and M. A. Lazar Mechanisms Regulating Adipocyte Expression of Resistin J. Biol. Chem., May 24, 2002; 277(22): 19754 - 19761. [Abstract] [Full Text] [PDF]

				Y. Li and M. A. Lazar Differential Gene Regulation by PPAR{gamma} Agonist and Constitutively Active PPAR{gamma}2 Mol. Endocrinol., May 1, 2002; 16(5): 1040 - 1048. [Abstract] [Full Text] [PDF]

				R. Cunard, M. Ricote, D. DiCampli, D. C. Archer, D. A. Kahn, C. K. Glass, and C. J. Kelly Regulation of Cytokine Expression by Ligands of Peroxisome Proliferator Activated Receptors J. Immunol., March 15, 2002; 168(6): 2795 - 2802. [Abstract] [Full Text] [PDF]